Avexitide and the LUCIDITY trial
Avexitide is an investigational GLP-1 receptor antagonist being developed for post-bariatric hypoglycemia, or PBH. Its purpose is to limit an excessive insulin response in a specific clinical setting. Amylyx’s November 5 update describes an upcoming LUCIDITY presentation and a planned FDA application, not an approval. 1 4
Why block a receptor that other medicines activate?
The earlier PREVENT study describes PBH as involving overstimulation of the gut: insulin system and excessive insulin-associated low blood glucose. It evaluated avexitide, also known as exendin (9–39), as a GLP-1 antagonist. The research question is therefore about preventing hypoglycemia after surgery, rather than producing weight loss. 4
PREVENT was a small Phase 2 crossover trial involving 18 women. Its meal-test and glucose-monitoring findings helped support further study, but that population and design should not be confused with the later parallel-group Phase 3 trial. The two studies provide different kinds of evidence. 4
What did the LUCIDITY trial evaluate?
The registered LUCIDITY study compares avexitide with placebo in adults with PBH following Roux-en-Y gastric bypass. Its main efficacy measure combines Level 2 and Level 3 hypoglycemic events over a 16-week blinded period. Safety, tolerability and anti-drug antibodies are also registered outcomes. 3
The registry snapshot still lists estimated enrollment of 75; Amylyx’s results release reports 78 participants. We retain that distinction instead of presenting a planning estimate as the final reported sample. The source and its date are especially useful when trial records and later announcements differ. 2 3
| Evidence | What it addresses |
|---|---|
| PREVENT, Phase 2 | Earlier crossover evidence in 18 women with PBH |
| LUCIDITY, Phase 3 | Hypoglycemic-event rates in the specified post-surgery population |
| Planned FDA application | A regulatory submission milestone, not an approval |
What results and adverse events were reported?
In its August 18 release, Amylyx reported a 55% reduction versus placebo in the composite event rate, with p=0.000003. The company also reported diarrhea and injection-site redness or bruising among common adverse events, and no serious adverse events considered related to avexitide. 2
The same release reported no body-weight change in either group during the blinded period. The event-rate reduction should not be rewritten as a percentage of patients cured, and the trial does not establish a weight-loss effect. Numerical results remain sponsor reporting pending fuller examination. 2
What is new in November, and what remains pending?
Amylyx says it will present LUCIDITY results at ObesityWeek in Washington, D.C., on November 15. It also says an FDA New Drug Application remains planned by the end of 2026. The earlier results and these new scheduling updates should appear as separate dates in a research timeline. 1
A positive clinical result, an application, FDA acceptance for review and an approval are different events. For this story, the most useful follow-up is to check the conference presentation and subsequent regulatory documents for the exact patient population, endpoint definitions and scope of any decision.
The antagonist terminology also needs to stay attached to the molecule. Sharing the GLP-1 receptor as a target does not make two drugs interchangeable, and an approved product acting on that receptor cannot be used as evidence that avexitide itself has been approved.
Scope for European readers
This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the research-use statement for the storefront's scope.